Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03246074 · ClinicalTrials.gov registry record · Phase 1
Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer
A Phase 1 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT03246074 is a Phase 1 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 35 participants.
The verdict
NCT03246074, a Phase 1 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
This research is being done to test the safety of the combination of the study drugs fostamatinib and paclitaxel. This study tests different doses of the drugs to see which doses are safest in people with ovarian cancer when given together.
Interventions
- DRUG Fostamatinib 100 mg bid and Paclitaxel
- DRUG Fostamatinib 150 mg bid and Paclitaxel
- DRUG Fostamatinib 200 mg bid and Paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2018-04-03 |
| Est. Completion | 2023-04-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03246074
The ClinicalTrials.gov registry entry for NCT03246074 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Fostamatinib 100 mg bid and Paclitaxel is the first listed.
NCT03246074 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03246074 about?
NCT03246074 is a clinical study titled "Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer". This research is being done to test the safety of the combination of the study drugs fostamatinib and paclitaxel. This study tests different doses of the drugs to see which doses are safest in people with ovarian cancer when given together.
What is the current status of trial NCT03246074?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2018-04-03. Estimated completion is 2023-04-03.
What interventions are being tested in trial NCT03246074?
The interventions under investigation include: Fostamatinib 100 mg bid and Paclitaxel (DRUG), Fostamatinib 150 mg bid and Paclitaxel (DRUG), Fostamatinib 200 mg bid and Paclitaxel (DRUG).
Who is sponsoring clinical trial NCT03246074?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.